CRISPR Therapeutics AG (CRSP)

Precedente Chiudi:

$53.91

Aprire:

$54.09

Volume 24 ore:

135.79K

Capitalizzazione di mercato:

$4.58B

Reddito:

$170.10M

Utile/perdita netta:

$-153.61M

Rapporto P/E:

-12.14

EPS:

-4.47

Flusso di cassa netto:

$-272.35M

1 W Prestazione:

-2.58%

1M Prestazione:

-20.45%

6M Prestazione:

+39.97%

1 anno Prestazione:

+10.80%

Intervallo 1D:

$54.07

$55.00

Portata 52W:

$37.55

$91.10

CRISPR Therapeutics AG Stock (CRSP) Company Profile

Nome

CRISPR Therapeutics AG

Settore

Healthcare (1191)

Industria

Biotechnology (688)

Telefono

41 41 561 3277

Indirizzo

Baarerstrasse 14, Zug

Dipendente

127

Cinguettio

@crisprtx

Prossima data di guadagno

2024-02-21

Ultimi documenti SEC

CRSP's Discussions on Twitter

CRISPR Therapeutics AG Stock (CRSP) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-02-15	Iniziato	Wolfe Research	Peer Perform
2023-12-11	Downgrade	TD Cowen	Market Perform → Underperform
2023-10-17	Downgrade	Cantor Fitzgerald	Overweight → Neutral
2023-09-27	Iniziato	Mizuho	Buy
2023-08-17	Aggiornamento	Citigroup	Neutral → Buy
2023-05-30	Iniziato	William Blair	Outperform
2023-04-13	Iniziato	Cantor Fitzgerald	Overweight
2023-03-21	Iniziato	Bernstein	Mkt Perform
2023-03-17	Iniziato	Bryan Garnier	Buy
2023-03-07	Iniziato	Robert W. Baird	Neutral
2022-10-11	Iniziato	Morgan Stanley	Underweight
2022-08-09	Downgrade	Barclays	Overweight → Equal Weight
2022-06-23	Downgrade	Evercore ISI	Outperform → In-line
2022-06-17	Iniziato	BMO Capital Markets	Outperform
2022-04-28	Iniziato	Credit Suisse	Neutral
2021-12-07	Iniziato	Cowen	Market Perform
2021-10-19	Iniziato	SVB Leerink	Outperform
2021-06-14	Aggiornamento	Citigroup	Sell → Neutral
2021-04-21	Aggiornamento	Jefferies	Hold → Buy
2021-03-04	Iniziato	JMP Securities	Mkt Outperform
2020-12-10	Reiterato	Chardan Capital Markets	Buy
2020-12-10	Downgrade	Jefferies	Buy → Hold
2020-12-10	Reiterato	Needham	Buy
2020-12-07	Downgrade	Wells Fargo	Overweight → Equal Weight
2020-10-23	Iniziato	RBC Capital Mkts	Sector Perform
2020-10-05	Iniziato	BofA Securities	Buy
2020-07-28	Reiterato	Needham	Buy
2020-07-14	Iniziato	SunTrust	Buy
2020-06-15	Reiterato	Canaccord Genuity	Buy
2020-03-05	Iniziato	Stifel	Hold
2020-02-03	Downgrade	Evercore ISI	Outperform → In-line
2019-11-19	Aggiornamento	William Blair	Mkt Perform → Outperform
2019-11-12	Aggiornamento	Oppenheimer	Perform → Outperform
2019-08-01	Iniziato	Jefferies	Buy
2019-07-26	Iniziato	Canaccord Genuity	Buy
2019-06-10	Iniziato	ROTH Capital	Buy
2019-04-12	Iniziato	Evercore ISI	Outperform
2019-03-14	Iniziato	William Blair	Mkt Perform
2019-01-28	Downgrade	Goldman	Buy → Neutral
2019-01-22	Downgrade	Citigroup	Neutral → Sell

Mostra tutto

CRISPR Therapeutics AG Borsa (CRSP) Ultime notizie

CRISPR Therapeutics AG (CRSP) Ascends But Remains Behind Market: Some Facts to Note

Zacks Investment Research

Missed Out on Novo Nordisk? 2 Healthcare Stocks With Big Catalysts on the Horizon.

The Motley Fool

Vertex Pharmaceuticals Just Made 2 Big Moves. Is the Stock a Buy?

The Motley Fool

CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: Here's Why

Zacks Investment Research

CRISPR Therapeutics to Present Oral Presentation at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting

GlobeNewswire Inc.

Tracking Cathie Wood's ARK Invest 13F Portfolio - Q1 2024 Update

Seeking Alpha

CRISPR Therapeutics AG Azioni (CRSP) Dati Finanziari

CRISPR Therapeutics AG (CRSP) Reddito 2024

CRISPR Therapeutics AG (CRSP) Reddito netto 2024

CRISPR Therapeutics AG (CRSP) Flusso di cassa 2024

CRISPR Therapeutics AG (CRSP) Utile per azione 2024